Immunovative has invested in developing in-house capability for manufacturing of our unique products developed from the Mirror EffectTM technology platform. The production of living cell products derived from normal blood donors is a challenge. In order for products produced from a blood donor to become biological drugs, as opposed to just a medical process, the products must be able to consistently meet pre-determined safety, identity and functional characteristics.  There can be little deviation in the final product derived from different donors. In addition, the pre-defined characteristics must be preserved after inventory storage and shipping until the product reaches the patient. We have integrated a team of professionals in cell culture, immunology, bioengineering and logistics with facilities, equipment and a quality team to create, validate and operate a biological manufacturing operation that complies with international standards for Good Manufacturing Practices (GMP). Materials used in the manufacturing process can be traced from “vein-to-vein”. All operations are conducted in accordance with written instructions. Quality and safety are designed into every product.



Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals

Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more